Effectiveness of Spinal Cord Stimulation as Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Pilot Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Sponsor
- Prisma Health-Upstate
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Permanent Spinal Cord Stimulator Implantation
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is an observational based pilot study evaluating the use of spinal cord stimulators for the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.
Detailed Description
Cancer treatment, for many patients, results in painful side effects. As evidence mounts demonstrating the risks associated with long term opioid therapy, non-opioid modalities need to be developed. Spinal cord stimulators are implanted devices that modulate the pain signaling system in the spinal cord. This research hopes to determine if the use of a spinal cord stimulator in patients with chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.The primary endpoints will be the number of patients who undergo permanent implantation. The endpoints will measure pain with the Brief Pain Inventory Short Form visual analog scale. The sleep quality will be measured using the Pittsburgh Sleep Quality Assessment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient has persistent, severe peripheral neuropathy secondary to chemotherapy
Exclusion Criteria
- •Refusal to undergo a spinal cord stimulator procedure
Outcomes
Primary Outcomes
Permanent Spinal Cord Stimulator Implantation
Time Frame: 2 years
To determine the total number of patients who undergo permanent spinal cord stimulator implantation.
Secondary Outcomes
- Subjective Quality of Life Assessment: Pittsburgh Sleep Quality Assessment(2 years)
- Subjective Pain Assessment: Brief Pain Inventory-Short Form(2 years)